Mutagenicity of Several Classes of Antitumor Agents to Salmonella Typhimurium TA98, TA100, and TA921

Total Page:16

File Type:pdf, Size:1020Kb

Mutagenicity of Several Classes of Antitumor Agents to Salmonella Typhimurium TA98, TA100, and TA921 [CANCER RESEARCH 38, 2148-2156, July 1978] 0008-5472/78/0038-0000$02.00 Mutagenicity of Several Classes of Antitumor Agents to Salmonella typhimurium TA98, TA100, and TA921 Yuko Seino,2 Minako Nagao, Takie Yahagi, Akio Hoshi, Takashi Kawachi, and Takashi Sugimura Biochemistry [Y. S., M. N., T. Y., 7. K., T. S.] and Pharmacology [A. H.¡Divisions, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo 104, Japan ABSTRACT Chemicals. Adriamycin hydrochloride, 5-fluorouracil, mi tomycin C, and L-asparaginase were obtained from Kyowa The mutagenic activities of antitumor agents, including Hakko Kogyo Co., Ltd., Tokyo, Japan. Cyclophosphamide 5 antibiotics, 19 antimetabolites, 5 alkylating agents, 2 and vinblastine sulfate were purchased from Shionogi & alkaloids, 1 enzyme, and 1 adrenal steroid hormone, were Co., Ltd., Osaka, Japan; Methotrexate and busulfan were tested on Salmonella typhimurium TA100, TA98, and TA92. from Takeda Chemical Industries. Ltd., Osaka, Japan; 1-/3- Four of these, busulfan, carbazilquinone, 1-(4-amino-2- D-arabinofuranosylcytosine and cyclocytidine were from methy Ipy rim idine - 5 - yl)met hyI- 3-(2-ch loroethy l)-3 -n itroso- Kohjin Co., Ltd., Tokyo, Japan. 6-Mercaptopurine and 8- urea hydrochloride, and pipobroman were shown for the azaguanine were from Sigma Chemical Co., St. Louis, Mo.; first time to be mutagenic. Further, the known mutagenic- ACNU3 and carbazilquinone were from Sankyo Co., Ltd., ities of five others, daunomycin hydrochloride, Adriamy- Tokyo, Japan; and actinomycin D was from Nippon Merck- cin hydrochloride, mitomycin C, 6-mercaptopurine, and Banyu Co., Ltd., Tokyo, Japan. Bleomycin hydrochloride cyclophosphamide, were confirmed. was from Nippon Kayaku Co., Ltd., Tokyo, Japan; dauno mycin hydrochloride was from Meiji Seika Kaisha, Tokyo, INTRODUCTION Japan; and FT-207 was from Taiho Pharmaceutical Co., Ltd., Tokyo, Japan. Alkylcarbamoyl derivatives of 5-fluo Many chemotherapeutic agents are now widely used clinically for treatment of cancers and leukemias and some rouracil were synthesized at Mitsui Pharmaceuticals, Inc., times for prophylaxis of recurrent cancer after surgical Tokyo, Japan. Vincristine sulfate was from Eli Lilly & Co., treatment. Indianapolis, Ind., and pipobroman was from Dainippon However, a phenomenon known as Haddow's paradox Pharmaceutical Co., Ltd., Osaka, Japan. Prednisolone was from Sanwa Research Institute, Tokyo, Japan. Glucose 6- (5) is that some cancer chemotherapeutic agents are car phosphate, glucose-6-phosphate dehydrogenase (EC cinogenic to laboratory animals and also induce chromo somal aberrations in cultured mammalian cells. Thus, it is 1.1.1.49), and ATP were from Sigma; NADH and NADPH important to know whether chemotherapeutic agents are were from Oriental Yeast Co., Ltd., Tokyo, Japan; and carcinogenic. dimethyl sulfoxide, spectrophotometric grade, was from Recently, it has become widely accepted that many mu- Wako Pure Chemical, Inc., Osaka, Japan. tagens are carcinogens (15, 16, 24). Therefore, in this work Eight compounds for drug use contained some vehicle, we tested the mutagenic activities in S. typhimurium strains and the amounts of these compounds were expressed as TA100, TA98, and TA92 of various kinds of chemotherapeu fjiQof active principle. The names of these compounds and tic agents now in use or being tested for use in treatment of the amounts in 1 vial, 1 ampul, or 1 tablet were as follows: daunomycin-HCI (20 mg principle; actual weight, 120 mg/ human cancer. The compounds tested were antibiotics, vial), Adriamycin-HCI (10 mg principle; actual weight, 50 antimetabolites, alkylating agents, alkaloids, an enzyme, mg/vial), bleomycin-HCI (15 mg potency; actual weight, 8 and a hormone. mg/ampul), actinomycin D (0.5 mg principle; actual weight, MATERIALS AND METHODS 20.5 mg/vial), mitomycin C (0.996 mg principle; actual weight, 1 mg/vial), cyclophosphamide (500 mg principle; Microbes. S. typhimurium strains TA100, TA98, and TA92 actual weight, 725 mg/vial), L-asparaginase (10,000 ID; were kindly supplied by Dr. Bruce N. Ames, University of actual weight, 33 mg/vial), and prednisolone (5 mg princi California, Berkeley, Calif. TA100 and TA98 are uvrB and ple; actual weight, 153 mg/tablet). rfa (deep rough) mutants (1). TA92 has the capacity for Mutation Test. The mutation test was carried out by our excision repair and an intact lipopolysaccharide barrier modification (20) of the method of Ames ef al. (1). The test (LPS+) (1). TA100 and TA92 both contain the same base- chemical in 0.1 ml dimethyl sulfoxide or H,0 was placed in pair change mutation, and TA98 contains a frameshift a tube and mixed with 0.5 ml S-9 mix (150 /u.lof the S-9 mutation at his locus (1). All these strains carry R-factor fraction of rat liver pretreated with polychlorinated bi- plasmid pKM101 (1). phenyl, 2 /nmol NADPH, 2 ¿imolNADH,2.5 /¿molglucose 6- phosphate, 0.25 unit glucose-6-phosphate dehydrogenase, ' This work was supported ¡npart by Grants-in-Aid for Cancer Research 4 /Limol MgCIo, 16.5 /nmol KCI, and 50 /¿molsodium phos from the Ministry of Education, Science and Culture and the Ministry of phate buffer, pH 7.4 and 0.1 ml of culture of the bacterial Health and Welfare, Japan, and by the Princess Takamatsu Cancer Research Fund. 3 The abbreviations used are: ACNU, 1-(4-amino-2-methylpyrimidine-5- 2 To whom requests for reprints should be addressed. yl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; FT-207, 1-(2-tetra- Received April 14, 1977; accepted March 22, 1978. hydrofuryl)-5-fluorouracil. 2148 CANCER RESEARCH VOL. 38 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 1978 American Association for Cancer Research. Mutagenicity of Antitumor Agents tester strain (1 to 2 x 108 cells). Without metabolic activa in vivo and in vitro and mutation in mammalian cells in vitro tion 50 /¿molsodium phosphate buffer, pH 7.4, in 0.5 ml (14). Bleomycin hydrochloride was not mutagenic to TA100 were used instead of S-9 mix. The mixture was preincu- or TA98, with or without S-9 mix, but it is known to cause bated at 37°for 20 min and then mixed with 2 ml top agar DNA strand breakage (26). Actinomycin D, which binds (0.7% agar and 0.6% NaCI) at 45°andspread on a minimal- preferentially to dG-dC pairs of DNA (13) and inhibits DNA- glucose agar plate containing 0.1 /¿moleachL-histidine and dependent RNA synthesis (12), was not mutagenic to TA100 biotin. Plates were incubated at 37°for 2 days, and then or TA98 with or without S-9 mix. The in vivo carcinogenicity his+ revertant colonies were counted. of actinomycin D in rats has been reported (30). Actinomy cin D is also reported to have very weak mutagenic activity RESULTS AND DISCUSSION on mammalian cells cultured in vitro (14). Mitomycin C was not mutagenic to TA100 or TA98 but was weakly mutagenic The trivial names and structures of the 5 antibiotics, 19 to TA92, especially without S-9 mix, as shown in Table 2. antimetabolites, 5 alkylating agents, and other compounds Mitomycin C produces interstrand cross-linking of double- tested are shown in Tables 1,3,5, and 7, respectively, with stranded DNA (27). In this case uv repair-deficient strain the results of mutagenicity tests on them and information cells were killed and did not yield any mutants (19). TA92, on their carcinogenicities. which has uv repair capacity, gave more reversants than did Antibiotics. Results on the mutagenicities of the antibiot the spontaneous revertants. Mitomycin C produces tumors ics are listed in Table 2. The mutagenicities of daunomycin in vivo (30). Bleomycin hydrochloride and actinomycin D hydrochloride (16), Adriamycin hydrochloride (16), and mi- were not mutagenic but were toxic to TA100 and TA98, as tomycin C (17), which had been reported previously, were was mitomycin C. But these compounds were not muta confirmed. Daunomycin hydrochloride and Adriamycin hy genic to TA92 (Table 2). drochloride intercalate DNA (33), resulting in inhibition of Antimetabolites. Results on antimetabolites are listed in DMA-dependent DNA and RNA polymerases (32). These Table 4. 5-Fluorouracil, an inhibitor of thymidylate synthe- compounds were highly mutagenic to TA100 and TA98 tase, was not mutagenic to TA100 or TA98 with or without without S-9 mix, the latter showing more mutagenicity in S-9 mix, as shown in Table 4. 5-Fluorouracil had a strong TA98 than in TA100. Addition of S-9 mix reduced the lethal effect on cells at a concentration of 5 /¿g/plate activity. Clear dose-response activities of these compounds without S-9 mix. FT-207 also was not mutagenic to TA100 were obtained, as shown in Table 2. These compounds or TA98 with or without S-9 mix. These 2 compounds were have potent actions in producing malignant transformation also not mutagenic to TA92 with or without S-9 mix. Table 1 Trivial names, structures, mutagenicities, and carcinogenicities of antibiotics Trivial name Structure Mutagenicity Carcinogenicity Daunomycin-MCI + (14) Adriamycin-HOI + (14) OH NH2 Ft: —CH3, daunomycin —CHjOH, Adriamycin Bleomycin-MCI Glycopeptide Actinomycin D + (30) Peptide Peptide CO CO Mitomycin C° + (30) Mitomycin C is mutagenic to S. typhimurium TA92. JULY 1978 2149 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 1978 American Association for Cancer Research. V. Se/no ef al. Table 2 Results of mutation tests on antibiotics his* revertants/plate TA100Drug"Daunomycin-HCIAdriamycin-HCIBleomycin-HCIActinomycin rowortantc/+ S-9mix144160 S-9mix286295 S-9mix24273362242827223155106423443252320221218172130212121221719-S-9mix340852 S-9mix4648494945282014484840806139-S-9 mix nmol*2800 (8,-)c3130(8, 0.420.830.020.050.10.20.5125100.941.884.79.418.82.46.112.20.011.02.5510+16314710913015215927030317018516899111125129106125100661471471107075103131-20214410630923498723620670190143100010390451321150000122TA98+1555136810232355610347762606445017187001815181626000017TA92fWo+ -)393732 02892434 DControl''Mitomycin 0323690120 CControl*"/itg/plate0.0830.17 43(2,-)1377226 " Drug contained some vehicle, and the amount of the drug was expressed as /*g of active principle.
Recommended publications
  • Induction with Mitomycin C, Doxorubicin, Cisplatin And
    British Journal of Cancer (1999) 80(12), 1962–1967 © 1999 Cancer Research Campaign Article no. bjoc.1999.0627 Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study RL Hong1, TS Sheen2, JY Ko2, MM Hsu2, CC Wang1 and LL Ting3 Departments of 1Oncology, 2Otolaryngology and 3Radiation Therapy, National Taiwan University Hospital, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10016, Taiwan Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia.
    [Show full text]
  • The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • And Grand Overview
    Welcome and Grand Overview Rose Aurigemma, PhD Acting Associate Director, Developmental Therapeutics Program Division of Cancer Treatment & Diagnosis, NCI July 23, 2021 Thank You to the Organizing Committee Weiwei Chen, Program Director, PTGB, DTP Rachelle Salomon, Program Director, BRB, DTP Sharad Verma, Program Director, PTGB, DTP Jason Yovandich, Chief, BRB, DTP Sundar Venkatachalam, Chief, PTGB, DTP 2 Introduction to the Developmental Therapeutics Program In 1955, congress created the Cancer Chemotherapy National Service Center which evolved, both structurally and functionally, into today’s Developmental Therapeutics Program (DTP). DTP’s involvement in the discovery or development of many anticancer therapeutics on the market today demonstrates its indelible impact on efforts to improve the health and well-being of people with cancer. 3 Approved Cancer Therapies with DTP Assistance 2018 Moxetumomab pasudotox-tdfk 1983 Etoposide (NSC 141540) 2015 Dinutuximab (Unituxin, NSC 764038) 1982 Streptozotocin (NSC 85998) Ecteinascidin 743 (NSC 648766) 1979 Daunorubicin (NSC 82151) 2012 Omacetaxine (homoharringtonine, NSC 141633) 1978 Cisplatin (cis-platinum) (NSC 119875) 2010 Eribulin (NSC 707389) 1977 Carmustine (BCNU) (NSC 409962) Sipuleucel-T (NSC 720270) 1976 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosurea (CCNU) 2009 Romidepsin (NSC 630176) (NSC 9037) Pralatrexate (NSC 713204) 1975 Dacarbazine (NSC 45388) 2004 Azacitidine (NSC 102816) 1974 Doxorubicin (NSC 123127) Cetuximab (NSC 632307) Mitomycin C (NSC 26980) 2003 Bortezomib (NSC 681239) 1973
    [Show full text]
  • Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
    Published OnlineFirst September 20, 2013; DOI: 10.1158/2159-8290.CD-13-0350 RESEARCH ARTICLE Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia Tea Pemovska 1 , Mika Kontro 2 , Bhagwan Yadav 1 , Henrik Edgren 1 , Samuli Eldfors1 , Agnieszka Szwajda 1 , Henrikki Almusa 1 , Maxim M. Bespalov 1 , Pekka Ellonen 1 , Erkki Elonen 2 , Bjørn T. Gjertsen5 , 6 , Riikka Karjalainen 1 , Evgeny Kulesskiy 1 , Sonja Lagström 1 , Anna Lehto 1 , Maija Lepistö1 , Tuija Lundán 3 , Muntasir Mamun Majumder 1 , Jesus M. Lopez Marti 1 , Pirkko Mattila 1 , Astrid Murumägi 1 , Satu Mustjoki 2 , Aino Palva 1 , Alun Parsons 1 , Tero Pirttinen 4 , Maria E. Rämet 4 , Minna Suvela 1 , Laura Turunen 1 , Imre Västrik 1 , Maija Wolf 1 , Jonathan Knowles 1 , Tero Aittokallio 1 , Caroline A. Heckman 1 , Kimmo Porkka 2 , Olli Kallioniemi 1 , and Krister Wennerberg 1 ABSTRACT We present an individualized systems medicine (ISM) approach to optimize cancer drug therapies one patient at a time. ISM is based on (i) molecular profi ling and ex vivo drug sensitivity and resistance testing (DSRT) of patients’ cancer cells to 187 oncology drugs, (ii) clinical implementation of therapies predicted to be effective, and (iii) studying consecutive samples from the treated patients to understand the basis of resistance. Here, application of ISM to 28 samples from patients with acute myeloid leukemia (AML) uncovered fi ve major taxonomic drug-response sub- types based on DSRT profi les, some with distinct genomic features (e.g., MLL gene fusions in subgroup IV and FLT3 -ITD mutations in subgroup V). Therapy based on DSRT resulted in several clinical responses.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Sex-Specific Effects of Cytotoxic Chemotherapy Agents
    www.impactaging.com AGING, April 2016, Vol 8 No 4 Research Paper Sex‐specific effects of cytotoxic chemotherapy agents cyclophospha‐ mide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus – an aging connection 1 2 2 2 Anna Kovalchuk , Rocio Rodriguez‐Juarez , Yaroslav Ilnytskyy , Boseon Byeon , Svitlana 3,4 4 3 1,5,6 2,5 Shpyleva , Stepan Melnyk , Igor Pogribny , Bryan Kolb, , and Olga Kovalchuk 1 Department of Neuroscience, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 2 Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 3 Division of Biochemical Toxicology, Food and Drug Administration National Center for Toxicological Research, Jefferson, AR 72079, USA 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA 5 Alberta Epigenetics Network, Calgary, AB, T2L 2A6, Canada 6 Canadian Institute for Advanced Research, Toronto, ON, M5G 1Z8, Canada Key words: chemotherapy, chemo brain, epigenetics, DNA methylation, DNA hydroxymethylation, oxidative stress, transcriptome, aging Received: 01/08/16; Accepted: 01/30/1 6; Published: 03/30/16 Corresponden ce to: Bryan Kolb, PhD; Olga Kovalchuk, PhD; E‐mail: [email protected]; [email protected] Copyright: Kovalchuk et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract: Recent research shows that chemotherapy agents can be more toxic to healthy brain cells than to the target cancer cells. They cause a range of side effects, including memory loss and cognitive dysfunction that can persist long after the completion of treatment.
    [Show full text]
  • Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly Developed with the Society of Urologic Nurses and Associates (SUNA)
    Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly developed with the Society of Urologic Nurses and Associates (SUNA) Revised: June 2020 Workgroup Members: AUA: Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD SUNA: Debbie Hensley, RN; Christy Krieg, MSN, CUNP; Leanne Schimke, MSN, CUNP I. Statement of Purpose: To define the performance guidance surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBC, urothelial carcinoma). II. Population: Adult Urology III. Definition: Intravesical therapy involves instillation of a therapeutic agent directly into the bladder via insertion of a urethral catheter. IV. Indications: For administration of medication directly into the bladder via catheterization utilizing sterile technique for NMIBC treatment. V. Guidelines and Principles: Health care personnel (MD, NP, PA, RN, LPN, or MA) performing intravesical therapy must be educated, demonstrate competency, and understand the implications of non-muscle invasive bladder cancer. (Scope of practice for health care personnel listed may vary based on state or institution). This should include associated health and safety issues regarding handling of cytotoxic, and immunotherapeutic agents; and documented competency of safe practical skills. At a minimum, each institution or office practice setting should implement an established, annual competency program to review safety work practices and guidelines regarding storage, receiving, handling/ transportation, administration, disposal, and handling a spill of hazardous drugs. (Mellinger, 2010) VI.
    [Show full text]
  • For Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline
    ANTICANCER RESEARCH 36: 419-426 (2016) Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline KATRIN ALMSTEDT1, PETER A. FASCHING1, ANTON SCHARL2, CLAUDIA RAUH1, BRIGITTE RACK3, ALEXANDER HEIN1, CAROLIN C. HACK1, CHRISTIAN M. BAYER1, SEBASTIAN M. JUD1, MICHAEL G. SCHRAUDER1, MATTHIAS W. BECKMANN1 and MICHAEL P. LUX1 1Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany; 2Department of Gynecology and Obstetrics, St. Marien Hospital, Amberg, Germany; 3Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany Abstract. Background/Aim: The aim of this single-arm, (MBC) is still a challenge. The majority of patients with prospective, multicenter phase II trial (MiX) was to increase breast cancer receive an anthracycline-based regimen as first treatment options for women with metastatic breast cancer chemotherapy, in an adjuvant, neoadjuvant, or metastatic pretreated with anthracycline and taxane by evaluation of the setting. The development of drug resistance and impairment efficacy and toxicity of the combination of mitomycin C and of organ functions limits the choice of further cytotoxic capecitabine. Patients and Methods: From 03/2004 to drugs in the metastatic situation. Although many patients are 06/2007, a total of 39 patients were recruited and received willing to receive further anticancer therapy to counteract mitomycin C in combination with capecitabine. The primary tumor growth, they often request a less toxic but still end-point was to determinate the tumor response according effective therapy. At present taxanes (e.g. paclitaxel, to Response Evaluation Criteria in Solid Tumors and the rate docetaxel, nab-paclitaxel), eribulin, vinorelbine, 5- of toxicities (safety).
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - [email protected] HEIKKI KUUSANMÄKI - [email protected] Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Recent Advances in the Management of Hormone Refractory Prostate Cancer
    Korean J Uro-Oncol 2004;2(3):147-153 Recent Advances in the Management of Hormone Refractory Prostate Cancer Mari Nakabayashi, William K. Oh Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA A typical treatment strategy after AAWD is to use secondary INTRODUCTION hormonal manipulations, although studies have not yet demonstrated a survival benefit with this class of treatment. Prostate cancer is the most common cancer in men in the Options in this category include (1) the secondary use of anti- United States and accounted for 29,900 deaths in 2003.1 androgens (e.g., high-dose bicalutamide, nilutamide), (2) thera- Although most men with advanced prostate cancer respond pies targeted against adrenal steroid synthesis (e.g., ketocona- initially to androgen deprivation therapies (ADT) by either zole, corticosteroids), and (3) estrogenic therapies (e.g. diethy- bilateral orchiectomy or leuteinizing hormone releasing hor- lstilbestrol). Symptomatic improvement and PSA responses mone (LHRH) analogues, patients eventually progress to an (defined as PSA decline >50% after treatment) have been androgen-independent state in which the initial ADT no longer reported in approximately 20% to 80% of patients with is adequate to control disease.2 Progression of the disease hormone-refractory prostate cancer (HRPC) with a typical manifests as an increase in serum prostate-specific antigen duration of response of 2 to 6 months. Toxicity is generally (PSA) or may be accompanied by radiographic evidence of mild for these oral therapies, although serious side effects, tumor growth. Here we report a brief summary of recent including adrenal insufficiency, liver toxicity, and thrombosis, advances in the management of hormone refractory prostate may occur (Table 1).
    [Show full text]